Bormioli Pharma grew North America gross sales by greater than 40% in 2022
3 min read
Bormioli Pharma, a worldwide chief partnering with prospects to offer complete packaging options for injectable medicine, in the present day introduced sturdy development in its North American enterprise in 2022, with gross sales growing greater than 40% year-over-year. The expansion in North America was matched by sturdy gross sales features within the firm’s markets worldwide, reflecting Bormioli’s multimillion greenback investments in increasing its capabilities as a supplier of complete packaging options for injectable medicine.
Established in 1825 as Bormioli Rocco, a producer of glass containers, Bormioli Pharma has an extended historical past innovating within the packaging trade. Now, as a strategic associate of many main drug producers, the corporate serves the pharmaceutical and biopharmaceutical markets with full packaging options, together with glass and plastic bottles, plastic and aluminum closures and equipment.
The U.S. glass bottle market is coping with persevering with provide points for injectable glass packaging on account of lingering results of the COVID-19 pandemic and ensuing provide chain disruptions. Bormioli is dedicated to offering a complete answer with its ever-expanding capabilities within the space of high-value glass vials, rubber stoppers and aluminum seals. Particularly, the corporate has invested in strengthening its tubular glass vials capabilities via superior equipment, whereas upgrading its platform for molded glass, and increasing clean-room capabilities for the manufacturing of rubber stoppers. These developments have been supported by current acquisitions that allow Bormioli to reliably and effectively produce rubber and aluminum closures, in addition to tubular glass vials.
For nearly 200 years, we have now been main the sector of molded glass manufacturing and now we have now expanded these capabilities to tubular glass vials designed for injectable medicine and vaccines.
Our proud historical past is matched by our present ardour for innovation within the provision of modern complete packaging options for drug makers. As a single provider of all of the parts of the injection drug equipment, we are able to supply all kinds of cost-effective, versatile options tailor-made to the shopper’s wants, whereas additionally pursuing an formidable agenda to vastly enhance the sustainability of all our operations. Our multi-faceted commitments are pushed by two main components – the provision chain points from the persevering with scarcity of glass packaging for injectable medicine and the stark reminders of the inescapable risks of ongoing local weather change.”
Andrea Lodetti, Chief Government Officer, Bormioli Pharma.
Bormioli Pharma’s merchandise assist to make sure most drug stability by defending medicine from deterioration, prolonging treatment stability, and offering correct dosing, thereby contributing to the well being of people receiving remedy.
In anticipation of its upcoming 200th anniversary, Bormioli Pharma launched “50-in-5,” an formidable program to attain 50% of sustainable uncooked supplies in its pharmaceutical packaging manufacturing by 2025. “50-in-5” is a venture impacting the complete manufacturing footprint. To attain this formidable purpose, the corporate has been strengthening and increasing its industrial platform, with investments of greater than 50 million euros to this point that can be matched by comparable investments over the subsequent three years. Methods embody growing the share of recycled supplies all through the manufacturing course of and adopting carbon seize and different inexperienced supplies for container closure parts and seals.
To be taught extra about this initiative and Bormioli’s complete packaging options, please see Bormioli executives at DCAT Week 2023 or contact an on-site devoted U.S. gross sales consultant at [email protected].
